Calcium Signaling Inhibitor

About Tactical Therapeutics

Tactical Therapeutics is pioneering a novel approach to combat treatment-resistant cancers by inhibiting dysregulated calcium signaling, a key driver of tumor progression and therapy resistance. The company's initial focus is on glioblastoma, one of the most aggressive and difficult-to-treat solid tumors with very limited treatment options and poor patient outcomes. By targeting a fundamental cellular pathway involved in cancer cell survival, Tactical aims to develop a new class of therapeutics that could work alone or in combination with existing treatments. Its success hinges on validating this mechanism in clinical settings and navigating the high-risk development pathway for CNS-active oncology drugs.

Therapeutic Areas